Group A Immunoglobulin G2 Geometric Mean Concentrations for Randomized Vaccine Groups, Weeks 0–44, With a Primary Vaccine Administered at Week 0 and Revaccination at Week 40
| Primary Vaccine . | Group A–Specific IgG2 GMCs (95% CI), µg/mL . | |||||
|---|---|---|---|---|---|---|
| Week 0 . | Week 4 . | Week 40 . | Revaccination . | Week 41 . | Week 44 . | |
| PsA-TTa | 0.10 (.08–.12) | 6.27 (5.25–7.50) | 0.76 (.63–.91) | PsA-TT | 36.12 (25.22–51.75) | 33.27 (23.02–48.06) |
| PsACWY | 13.27 (10.26–17.18) | 15.24 (11.78–19.72) | ||||
| Hib-TT | 0.70 (.48–1.00) | 0.71 (.44–1.15) | ||||
| PsACWYb | 0.14 (.11–.16) | 0.97 (.80–1.18) | 0.36 (.29–.44) | PsA-TT | 15.97 (11.70–21.80) | 26.82 (19.65–36.61) |
| PsACWY | 2.04 (1.39–2.98) | 2.25 (1.53–3.31) | ||||
| Hib-TT | 0.32 (.24–.42) | 0.25 (.17–.37) | ||||
| Hib-TTc | NA | NA | 0.14 (.12–.17) | PsA-TT | 3.46 (2.06–5.80) | 7.83 (3.72–16.47) |
| PsACWY | 0.52 (.29–.94) | 1.15 (.60–2.18) | ||||
| Hib-TT | 0.17 (.13–.23) | 0.14 (.10–.20) | ||||
| Primary Vaccine . | Group A–Specific IgG2 GMCs (95% CI), µg/mL . | |||||
|---|---|---|---|---|---|---|
| Week 0 . | Week 4 . | Week 40 . | Revaccination . | Week 41 . | Week 44 . | |
| PsA-TTa | 0.10 (.08–.12) | 6.27 (5.25–7.50) | 0.76 (.63–.91) | PsA-TT | 36.12 (25.22–51.75) | 33.27 (23.02–48.06) |
| PsACWY | 13.27 (10.26–17.18) | 15.24 (11.78–19.72) | ||||
| Hib-TT | 0.70 (.48–1.00) | 0.71 (.44–1.15) | ||||
| PsACWYb | 0.14 (.11–.16) | 0.97 (.80–1.18) | 0.36 (.29–.44) | PsA-TT | 15.97 (11.70–21.80) | 26.82 (19.65–36.61) |
| PsACWY | 2.04 (1.39–2.98) | 2.25 (1.53–3.31) | ||||
| Hib-TT | 0.32 (.24–.42) | 0.25 (.17–.37) | ||||
| Hib-TTc | NA | NA | 0.14 (.12–.17) | PsA-TT | 3.46 (2.06–5.80) | 7.83 (3.72–16.47) |
| PsACWY | 0.52 (.29–.94) | 1.15 (.60–2.18) | ||||
| Hib-TT | 0.17 (.13–.23) | 0.14 (.10–.20) | ||||
Abbreviations: CI, confidence interval; GMC, geometric mean concentration; IgG2, immunoglobulin G2; NA, not applicable.
a Group A meningococcal conjugate vaccine.
b Meningococcal group A, C, W, Y polysaccharide vaccine.
cHaemophilus influenzae type b conjugate vaccine.
Group A Immunoglobulin G2 Geometric Mean Concentrations for Randomized Vaccine Groups, Weeks 0–44, With a Primary Vaccine Administered at Week 0 and Revaccination at Week 40
| Primary Vaccine . | Group A–Specific IgG2 GMCs (95% CI), µg/mL . | |||||
|---|---|---|---|---|---|---|
| Week 0 . | Week 4 . | Week 40 . | Revaccination . | Week 41 . | Week 44 . | |
| PsA-TTa | 0.10 (.08–.12) | 6.27 (5.25–7.50) | 0.76 (.63–.91) | PsA-TT | 36.12 (25.22–51.75) | 33.27 (23.02–48.06) |
| PsACWY | 13.27 (10.26–17.18) | 15.24 (11.78–19.72) | ||||
| Hib-TT | 0.70 (.48–1.00) | 0.71 (.44–1.15) | ||||
| PsACWYb | 0.14 (.11–.16) | 0.97 (.80–1.18) | 0.36 (.29–.44) | PsA-TT | 15.97 (11.70–21.80) | 26.82 (19.65–36.61) |
| PsACWY | 2.04 (1.39–2.98) | 2.25 (1.53–3.31) | ||||
| Hib-TT | 0.32 (.24–.42) | 0.25 (.17–.37) | ||||
| Hib-TTc | NA | NA | 0.14 (.12–.17) | PsA-TT | 3.46 (2.06–5.80) | 7.83 (3.72–16.47) |
| PsACWY | 0.52 (.29–.94) | 1.15 (.60–2.18) | ||||
| Hib-TT | 0.17 (.13–.23) | 0.14 (.10–.20) | ||||
| Primary Vaccine . | Group A–Specific IgG2 GMCs (95% CI), µg/mL . | |||||
|---|---|---|---|---|---|---|
| Week 0 . | Week 4 . | Week 40 . | Revaccination . | Week 41 . | Week 44 . | |
| PsA-TTa | 0.10 (.08–.12) | 6.27 (5.25–7.50) | 0.76 (.63–.91) | PsA-TT | 36.12 (25.22–51.75) | 33.27 (23.02–48.06) |
| PsACWY | 13.27 (10.26–17.18) | 15.24 (11.78–19.72) | ||||
| Hib-TT | 0.70 (.48–1.00) | 0.71 (.44–1.15) | ||||
| PsACWYb | 0.14 (.11–.16) | 0.97 (.80–1.18) | 0.36 (.29–.44) | PsA-TT | 15.97 (11.70–21.80) | 26.82 (19.65–36.61) |
| PsACWY | 2.04 (1.39–2.98) | 2.25 (1.53–3.31) | ||||
| Hib-TT | 0.32 (.24–.42) | 0.25 (.17–.37) | ||||
| Hib-TTc | NA | NA | 0.14 (.12–.17) | PsA-TT | 3.46 (2.06–5.80) | 7.83 (3.72–16.47) |
| PsACWY | 0.52 (.29–.94) | 1.15 (.60–2.18) | ||||
| Hib-TT | 0.17 (.13–.23) | 0.14 (.10–.20) | ||||
Abbreviations: CI, confidence interval; GMC, geometric mean concentration; IgG2, immunoglobulin G2; NA, not applicable.
a Group A meningococcal conjugate vaccine.
b Meningococcal group A, C, W, Y polysaccharide vaccine.
cHaemophilus influenzae type b conjugate vaccine.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
